UY30385A1 - Vacuna recombinante contra el virus de la lengua azul - Google Patents
Vacuna recombinante contra el virus de la lengua azulInfo
- Publication number
- UY30385A1 UY30385A1 UY30385A UY30385A UY30385A1 UY 30385 A1 UY30385 A1 UY 30385A1 UY 30385 A UY30385 A UY 30385A UY 30385 A UY30385 A UY 30385A UY 30385 A1 UY30385 A1 UY 30385A1
- Authority
- UY
- Uruguay
- Prior art keywords
- btv
- composition
- virus
- language
- blue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
Abstract
La presente invencion se refiere a una composicion inmunogénica o de vacuna para inducir una respuesta inmune protectora contra los Orbivirus, más específicamente contra el virus de la lengua azul (BTV) , en un anima susceptible de infectarse con BTV. La composicion puede incluir un vehículo o excipiente aceptable desde el punto de vista farmacéutico o veterinario, y un vector. El vector puede contener una molécula o moléculas heterologa(s) de ácidos nucleicos, expresa in vivo en el animal un antígeno, inmunogeno o epitopo de estos del BTV, p. ej. BTV BP2; BTV BP2 y BP5; BTV BP2 y BP5 y BP3 y/o BP7. La composicion puede contener un adyuvante, como por ejemplo un carbomero. Se contemplan asimismo métodos para elaborar y utilizar dicha composicion, incluso AGACAGTGGTCAATTCCAATGGTACTGTTTGACGATAC
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/444,698 US7862821B2 (en) | 2006-06-01 | 2006-06-01 | Recombinant vaccine against bluetongue virus |
Publications (1)
Publication Number | Publication Date |
---|---|
UY30385A1 true UY30385A1 (es) | 2008-01-02 |
Family
ID=38790493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY30385A UY30385A1 (es) | 2006-06-01 | 2007-06-01 | Vacuna recombinante contra el virus de la lengua azul |
Country Status (17)
Country | Link |
---|---|
US (1) | US7862821B2 (es) |
EP (2) | EP2816057B1 (es) |
CN (2) | CN101754975B (es) |
AR (1) | AR061152A1 (es) |
AU (1) | AU2007293474C9 (es) |
BR (1) | BRPI0712191A2 (es) |
CA (1) | CA2653696C (es) |
ES (1) | ES2623138T3 (es) |
HK (1) | HK1200180A1 (es) |
IL (1) | IL195641A (es) |
MA (1) | MA30569B1 (es) |
NZ (1) | NZ573435A (es) |
RU (1) | RU2446823C2 (es) |
TW (1) | TWI399213B (es) |
UY (1) | UY30385A1 (es) |
WO (1) | WO2008030282A2 (es) |
ZA (1) | ZA200810826B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070280690A1 (en) * | 2006-06-02 | 2007-12-06 | Fujitsu Limited | System and Method for Managing Power in an Optical Network |
CL2008001806A1 (es) * | 2007-06-20 | 2008-09-05 | Wyeth Corp | Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion. |
GB0805356D0 (en) * | 2008-03-25 | 2008-04-30 | Isis Innovation | Vaccine adjuvant composition |
AP3334A (en) * | 2008-10-24 | 2015-07-31 | Univ California | Vaccine against african horse sickness virus |
US20110110980A1 (en) * | 2009-09-02 | 2011-05-12 | Wyeth Llc | Heterlogous prime-boost immunization regimen |
US9345759B2 (en) | 2010-03-12 | 2016-05-24 | Merial, Inc. | Bluetongue virus recombinant vaccines and uses thereof |
WO2011131208A1 (fr) * | 2010-04-22 | 2011-10-27 | Institut Pasteur D'algerie | Vaccin bivalent a usage vétérinaire anti-entérotoxémie |
WO2013057236A1 (en) * | 2011-10-21 | 2013-04-25 | Intervet International B.V. | Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens |
EP2814506B1 (en) | 2012-02-14 | 2018-11-28 | Merial, Inc. | Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom |
KR102136437B1 (ko) | 2012-06-13 | 2020-07-21 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 재조합체 btv 및 ahsv 백신 |
JP2015533478A (ja) * | 2012-08-29 | 2015-11-26 | インターベット インターナショナル ベー. フェー. | マーカーワクチン |
CN103305473B (zh) * | 2013-06-18 | 2015-01-07 | 中国农业科学院哈尔滨兽医研究所 | 抗蓝舌病病毒血清1型vp2蛋白的单克隆抗体btv1-4b6及其识别的b细胞表位多肽与应用 |
CN103305472A (zh) * | 2013-06-18 | 2013-09-18 | 中国农业科学院哈尔滨兽医研究所 | 抗蓝舌病病毒血清1型vp2蛋白的单克隆抗体btv1-3e8及其识别的b细胞表位多肽与应用 |
CN104258138A (zh) * | 2014-09-28 | 2015-01-07 | 山东新希望六和集团有限公司 | 一种用于治疗牛蓝舌病的药物组合物及其制备方法 |
EP3768326A1 (en) * | 2018-03-19 | 2021-01-27 | Boehringer Ingelheim Vetmedica GmbH | Ehv insertion site ul43 |
CN110551634A (zh) * | 2019-09-04 | 2019-12-10 | 中国农业科学院兰州兽医研究所 | 一种山羊支原体山羊肺炎亚种分离培养方法 |
CN110551653A (zh) * | 2019-09-04 | 2019-12-10 | 中国农业科学院兰州兽医研究所 | 一种无血清制备牛支原体抗原的方法 |
CN113308441B (zh) * | 2021-06-02 | 2022-05-10 | 华中农业大学 | 一株猫疱疹病毒i型病毒株及其应用 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4963481A (en) | 1985-12-18 | 1990-10-16 | Genetics Institute Inc | Promoter system |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
DK175363B1 (da) | 1986-09-12 | 2004-09-13 | Genentech Inc | Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren |
IE872748L (en) | 1986-10-16 | 1988-04-16 | Arjomari Europ | Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
DE3743138A1 (de) | 1987-12-18 | 1989-09-14 | Mayr Christian Gmbh & Co Kg | Schleifringlose, elektromagnetische ueberlastkupplung |
WO1990001543A1 (fr) | 1988-07-29 | 1990-02-22 | Intracel Corporation | Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo |
CA2003300A1 (en) | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Skin test and test kit for aids |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
US5552143A (en) | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
GB9001766D0 (en) | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
US5514375A (en) | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
KR100242671B1 (ko) | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
US5382425A (en) | 1992-01-13 | 1995-01-17 | Syntro Corporation | Recombinant swinepox virus |
US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
FR2702373B1 (fr) | 1993-03-08 | 1996-06-07 | Rhone Merieux | Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable. |
US5830463A (en) * | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
US6485729B1 (en) | 1993-09-13 | 2002-11-26 | Protein Sciences Corporation | Neuraminidase-supplemented compositions |
EP0668355B1 (en) | 1993-12-20 | 1999-04-07 | Akzo Nobel N.V. | Vaccine for the protection of horses against equine herpesvirus infection |
US5529780A (en) | 1994-03-30 | 1996-06-25 | Virogenetics Corporation | Nucleotide and amino acid sequences of canine herpesvirus gB and gC |
FR2728795B1 (fr) | 1994-12-30 | 1997-03-21 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire |
FR2728794B1 (fr) | 1994-12-30 | 1997-03-21 | Rhone Merieux | Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro |
CA2214029A1 (en) | 1995-04-25 | 1996-10-31 | Magda Marquet | Single-vial formulations of dna/lipid complexes |
FR2741806B1 (fr) | 1995-11-30 | 1998-02-20 | Rhone Merieux | Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline |
US5858373A (en) | 1995-12-01 | 1999-01-12 | Virogenetics Corporation | Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them |
FR2750865B1 (fr) | 1996-06-27 | 1998-12-04 | Rhone Merieux | Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2 |
FR2750866B1 (fr) | 1996-06-27 | 1998-11-27 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
JP2002512501A (ja) | 1996-07-03 | 2002-04-23 | メリアル インコーポレイテッド | 外来性dnaを含む組換えイヌアデノウィルス(cav) |
US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
FR2751225B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
FR2751226B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies du cheval |
FR2751227B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
FR2751224B1 (fr) | 1996-07-19 | 1998-11-20 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs |
FR2751228B1 (fr) | 1996-07-19 | 1998-11-20 | Rhone Merieux | Vaccin polynucleotidique bovin pour voie intradermique |
FR2751229B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
FR2751223B1 (fr) | 1996-07-19 | 1998-12-04 | Rhone Merieux | Formule de vaccin polynucleotidique felin |
DE69733020T2 (de) | 1996-10-11 | 2006-02-16 | The Regents Of The University Of California, Oakland | Immunostimulierende oligonucleotidekonjugate |
ES2153654T3 (es) | 1996-10-17 | 2001-03-01 | Oxford Biomedica Ltd | Vectores retrovirales. |
FR2757061B1 (fr) | 1996-12-16 | 1999-03-26 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
FR2758986B1 (fr) | 1997-01-31 | 1999-04-30 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
US6368603B1 (en) | 1997-03-05 | 2002-04-09 | Merial Limited | Lyme combination compositions and uses |
US5990091A (en) * | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
WO1998042743A1 (en) | 1997-03-24 | 1998-10-01 | Merial | Canine ehrlichiosis immunogenic and diagnostic compositions and methods |
US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
US6391314B1 (en) | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
FR2781159B1 (fr) | 1998-07-06 | 2000-10-06 | Merial Sas | Vaccin circovirus et parvovirus porcin |
US6224882B1 (en) | 1997-11-07 | 2001-05-01 | Protein Science Corp. | Insect cells or fractions as adjuvant for antigens |
DK1895010T3 (da) | 1997-12-22 | 2011-11-21 | Oxford Biomedica Ltd | Vektorer baseret på virus for infektiøs hesteanæmi (eiav) |
US6294176B1 (en) | 1998-07-10 | 2001-09-25 | Schering-Plough Veterinary Corp. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
DE69928820D1 (de) | 1998-10-02 | 2006-01-12 | Caritas St Elizabeths Boston | Akt zusammensetzungen zur steigerung des überlebens von kardiomyozyten |
US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
AU782154C (en) | 1999-06-10 | 2006-02-09 | Boehringer Ingelheim Animal Health USA Inc. | DNA vaccines for pets and sport animals |
US6645740B1 (en) | 1999-06-10 | 2003-11-11 | Merial Limited | Nucleic acids encodings equine GM-CSF |
US6943152B1 (en) | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
ATE432269T1 (de) | 1999-10-08 | 2009-06-15 | Merial Sas | Polymorphe form b von 3-(cyclopropylmethoxy)-4- 4-(methylsulfonyl)phe yl -5,5-dimethyl-5h-furan-2- on |
NZ530805A (en) | 1999-12-21 | 2005-12-23 | Merial Sas | Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another pathogen |
FR2804028B1 (fr) | 2000-01-21 | 2004-06-04 | Merial Sas | Vaccins adn ameliores pour animaux de rente |
CA2311881C (en) | 2000-06-16 | 2007-08-28 | Gary O. Maupin | Control of arthropods in rodents |
US6455595B1 (en) | 2000-07-24 | 2002-09-24 | Chevron U.S.A. Inc. | Methods for optimizing fischer-tropsch synthesis |
US7740863B2 (en) | 2001-04-06 | 2010-06-22 | Merial | Recombinant vaccine against West Nile Virus |
FR2825280B1 (fr) | 2001-06-01 | 2005-04-15 | Merial Sas | Vaccination contre le virus de l'immunodeficience feline |
DE10260805A1 (de) | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins |
JP4902972B2 (ja) * | 2005-07-15 | 2012-03-21 | ルネサスエレクトロニクス株式会社 | 不揮発性記憶素子の制御方法 |
-
2006
- 2006-06-01 US US11/444,698 patent/US7862821B2/en active Active
-
2007
- 2007-05-30 BR BRPI0712191-1A patent/BRPI0712191A2/pt not_active Application Discontinuation
- 2007-05-30 AU AU2007293474A patent/AU2007293474C9/en active Active
- 2007-05-30 ES ES14170626.7T patent/ES2623138T3/es active Active
- 2007-05-30 WO PCT/US2007/012709 patent/WO2008030282A2/en active Application Filing
- 2007-05-30 CA CA2653696A patent/CA2653696C/en active Active
- 2007-05-30 NZ NZ573435A patent/NZ573435A/en unknown
- 2007-05-30 EP EP14170626.7A patent/EP2816057B1/en active Active
- 2007-05-30 RU RU2008152064/15A patent/RU2446823C2/ru active
- 2007-05-30 CN CN2007800270117A patent/CN101754975B/zh active Active
- 2007-05-30 EP EP07852372A patent/EP2029622A2/en not_active Ceased
- 2007-05-30 CN CN2012105485762A patent/CN103143034A/zh active Pending
- 2007-06-01 UY UY30385A patent/UY30385A1/es not_active Application Discontinuation
- 2007-06-01 AR ARP070102369A patent/AR061152A1/es not_active Application Discontinuation
- 2007-06-01 TW TW096119784A patent/TWI399213B/zh active
-
2008
- 2008-12-01 IL IL195641A patent/IL195641A/en active IP Right Grant
- 2008-12-23 ZA ZA200810826A patent/ZA200810826B/xx unknown
- 2008-12-26 MA MA31522A patent/MA30569B1/fr unknown
-
2015
- 2015-01-21 HK HK15100680.8A patent/HK1200180A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US7862821B2 (en) | 2011-01-04 |
EP2029622A2 (en) | 2009-03-04 |
CN101754975B (zh) | 2013-01-02 |
CA2653696C (en) | 2017-10-24 |
AU2007293474B2 (en) | 2012-07-19 |
MA30569B1 (fr) | 2009-07-01 |
CN103143034A (zh) | 2013-06-12 |
NZ573435A (en) | 2011-09-30 |
TW200810779A (en) | 2008-03-01 |
BRPI0712191A2 (pt) | 2012-03-06 |
IL195641A (en) | 2013-12-31 |
AU2007293474C1 (en) | 2014-06-05 |
US20070280960A1 (en) | 2007-12-06 |
HK1200180A1 (en) | 2015-07-31 |
CN101754975A (zh) | 2010-06-23 |
WO2008030282A3 (en) | 2009-12-17 |
EP2816057B1 (en) | 2017-02-01 |
IL195641A0 (en) | 2011-08-01 |
RU2008152064A (ru) | 2010-07-20 |
AR061152A1 (es) | 2008-08-06 |
RU2446823C2 (ru) | 2012-04-10 |
ZA200810826B (en) | 2009-11-25 |
ES2623138T3 (es) | 2017-07-10 |
EP2816057A1 (en) | 2014-12-24 |
TWI399213B (zh) | 2013-06-21 |
CA2653696A1 (en) | 2008-03-13 |
WO2008030282A2 (en) | 2008-03-13 |
AU2007293474A1 (en) | 2008-03-13 |
AU2007293474C9 (en) | 2014-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY30385A1 (es) | Vacuna recombinante contra el virus de la lengua azul | |
AR080515A1 (es) | Vacunas recombinantes del virus de la enfermedad del pie y de la boca (fmd1) y sus usos | |
WO2016007576A3 (en) | Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus | |
WO2007022151A3 (en) | Immunization of avians by administration of non-replicating vectored vaccines | |
JP2014534202A5 (es) | ||
CO6150189A2 (es) | Vacunas para malaria | |
JP2017530124A5 (es) | ||
CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
UA108081C2 (uk) | Модифікація рекомбінантного аденовірусу імуногенними епітопами білка circumsporozoite плазмодія | |
AR110632A1 (es) | Vectores del adenovirus canino | |
SI1951296T2 (sl) | Iz celic izpeljana virusna cepiva z nizko stopnjo preostale celiäśne dna z obdelavo z betapropiolaktonom | |
EA201070329A1 (ru) | Векторы и конструкции для доставки гриппозного антигена | |
EA201400912A1 (ru) | Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе | |
CA3010977A1 (en) | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus | |
CO2017001614A2 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
AR126891A2 (es) | Vacunas de subunidades de rotavirus, métodos de preparación y uso de las mismas | |
CL2021003211A1 (es) | Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018) | |
BRPI0813313A8 (pt) | Vetor poxvírus de racum recombinante, vacina da raiva recombinante, métodos para induzir uma resposta imunoprotetora para a raiva em um mamífero, e para produzir um vetor poxvírus de racum recombinante, e, plasmídeo pfd2003-gpv-pv. | |
EA201690115A1 (ru) | Комбинированные иммуногенные композиции | |
CU20120057A7 (es) | Composición vacunal contra el virus del dengue, kit y plásmido | |
BR112022003474A2 (pt) | Vacinas do vírus da hepatite b | |
ATE435660T1 (de) | Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen | |
UY31574A1 (es) | Vacunas contra la malaria | |
BR112014001287A2 (pt) | vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina | |
MX2022007217A (es) | Vacuna epitópica para virus de fiebre porcina africana. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RDES | Application refused |
Effective date: 20190117 |